Allopurinol is Safe and Effective to Achieve Biochemical and Histological Remission in Patients with Autoimmune Hepatitis with Incomplete Therapeutic Response

Falcão, Lydia Teófilo de Moraes; Ono, Shinya; Diniz, Márcio A.; Carrilho, F.J.; Cançado, Eduardo Luiz Rachid

doi:10.1016/s0168-8278(16)00712-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been demonstrated that mycophenolate mofetil (MMF) ( 5 , 44 – 51 ), methotrexate ( 52 ), 6-mercaptopurine ( 53 ), allopurinol ( 54 , 55 ), tacrolimus ( 8 , 45 , 56 – 59 ) and everolimus ( 60 ) are effective and well-tolerated in patients with AIH. Torisu et al ( 61 ) indicated that UDCA monotherapy may be considered for treatment of patients with AIH with a serum ALT level of <200 IU/l.…”

Section: Discussionmentioning

confidence: 99%

Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta‑analysis

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

The most suitable treatment regimen for autoimmune hepatitis (AIH) in adults remains unknown and requires further investigation. The current study therefore aimed to integrate evidence to provide hierarchies of the comparative efficacies of treatments measured by clinical and biochemical remission. A Bayesian-framework network meta-analysis of randomized controlled trials (RCTs) was preformed to compare eight treatments for AIH. Eligible RCTs were identified by searching Embase, Pubmed and the Cochrane Library for publications between 1966 and April 2017. All outcomes were independently extracted from the included studies by two authors. A total of six RCTs were subsequently included in the current study. The network of comparisons on remission indicated that patients treated with prednisone (pred) experienced significantly increased rates of remission compared with those treated with azathioprine [AZA; odds ratio (OR), 0.21; 95% confidence interval (CI), 0.06–0.71] and budesonide (bude) + AZA significantly increased remission compared with placebo treatment (OR, 36.66; 95% CI, 1.40–962.49) or AZA (OR, 10.30; 95% CI, 1.50–70.70). Based on the cumulative ranking probabilities, bude + AZA (89.4) was ranked first, pred (69.1) was ranked second, pred + AZA (63.2) was ranked third and placebo (7.8) treatment was ranked last. Bude + AZA may be the most appropriate candidate for the treatment of non-cirrhotic patients. However, bude + AZA as frontline therapy for AIH requires more large-scale studies with a longer duration of follow-up histology and a focus on dose-response. Additionally, development of other prospective treatments, which may be used as alternative therapy or first line therapy, and their subsequent evaluation in clinical RCTs is required.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta‑analysis

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

show abstract

Allopurinol is Safe and Effective to Achieve Biochemical and Histological Remission in Patients with Autoimmune Hepatitis with Incomplete Therapeutic Response

Cited by 1 publication

References 0 publications

Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta‑analysis

Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta‑analysis

Contact Info

Product

Resources

About